STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Schedule 13G/A: GS Group and Goldman Sachs & Co. Hold 0 Shares of CMRX

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed a Schedule 13G/A reporting that they beneficially own 0.00 shares of Chimerix common stock, representing 0.0% of the class. The cover pages show 0.00 sole and shared voting power and 0.00 sole and shared dispositive power, indicating no reportable economic or voting stake in the issuer as disclosed.

The filing includes a joint filing agreement and an exhibit identifying Goldman Sachs & Co. LLC as a subsidiary of The Goldman Sachs Group, Inc. It also states ownership is five percent or less and that the securities are held in the ordinary course of business and were not acquired to influence control.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Report shows no beneficial holdings—no direct market exposure or voting influence from Goldman Sachs entities.

The Schedule 13G/A discloses 0.00 shares and 0.0% ownership, with 0.00 reported voting and dispositive powers. For investors, this filing confirms that these large financial entities do not hold a reportable position in Chimerix and, per the certification, are not acting to influence control. The joint filing and subsidiary identification are administrative disclosures clarifying corporate relationships among the filers.

TL;DR: Disclosure is routine and non-material; it documents corporate relationships and ordinary-course holdings.

The document provides standard compliance information: a joint filing agreement and an exhibit stating the parent-subsidiary relationship. The filers certify the holdings are ordinary-course and not intended to affect corporate control. Because reported holdings are 0.00 shares, there are no governance or control implications arising from this filing itself.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



THE GOLDMAN SACHS GROUP, INC.
Signature:Name: Veronica Mupazviriwo
Name/Title:Attorney-in-fact
Date:07/17/2025
GOLDMAN SACHS & CO. LLC
Signature:Name: Veronica Mupazviriwo
Name/Title:Attorney-in-fact
Date:07/17/2025
Exhibit Information

EXHIBIT (99.1) JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, par value $0.001 per share, of CHIMERIX, INC. and further agree to the filing of this agreement as an Exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G. Date: 07/17/2025 THE GOLDMAN SACHS GROUP, INC. By:/s/ Veronica Mupazviriwo ---------------------------------------- Name: Veronica Mupazviriwo Title: Attorney-in-fact GOLDMAN SACHS & CO. LLC By:/s/ Veronica Mupazviriwo ---------------------------------------- Name: Veronica Mupazviriwo Title: Attorney-in-fact EXHIBIT (99.2) ITEM 7 INFORMATION The securities being reported on by The Goldman Sachs Group, Inc. ("GS Group"), as a parent holding company, are owned, or may be deemed to be beneficially owned, by Goldman Sachs & Co. LLC ("Goldman Sachs"), a broker or dealer registered under Section 15 of the Act and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940. Goldman Sachs is a subsidiary of GS Group.

FAQ

What does the Schedule 13G/A say about Goldman Sachs' stake in Chimerix (CMRX)?

The filing reports 0.00 shares, representing 0.0% of Chimerix common stock, indicating no beneficial ownership as disclosed.

Which entities filed the Schedule 13G/A for CMRX?

The filers are The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC.

Do the filers claim any voting or dispositive power over CMRX shares?

No. The cover pages report 0.00 sole and shared voting power and 0.00 sole and shared dispositive power.

Does the filing indicate a significant ownership (over 5%) of CMRX?

No. The filing states ownership is 5 percent or less of the class.

Is there a joint filing or subsidiary disclosure in the filing?

Yes. Exhibit (99.1) is a joint filing agreement and Exhibit (99.2) identifies Goldman Sachs & Co. LLC as a subsidiary of The Goldman Sachs Group, Inc.
Chimerix

NASDAQ:CMRX

CMRX Rankings

CMRX Latest News

CMRX Stock Data

354.50M
91.95M
Pharmaceutical Preparation Manufacturing
Pharmaceutical Preparations
Link
US
DURHAM